@TobiasInvest
Scientifically, 300 patients RCT trial would give much more data and can stand up to scrutiny vs if the trial was stopped early.
But, the 30% review mark is in the trial design, agreed with FDA and is judged by an independent group.
Ideally, I would like to see Mesoblast get approval, at the 30% mark, but then continue with the trial in a confirmation basis (maybe, without the placebo group)... but, I'm not too sure if the trial protocols would allow that.
Cell Therapy News/Articles, page-2974
-
- There are more pages in this discussion • 15,466 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
0.280(18.4%) |
Mkt cap ! $2.009B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.82 | $1.71 | $20.89M | 11.77M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 149 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 18913 | 7 |
View Market Depth
| Last trade - 13.17pm 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |